There are no clinical data/markers to predict improved survival in patients with hepatocellular carcinoma treated with sorafenib. Majority of sorafenib adverse events appear within the first 60 days of treatment and studies correlating them with outcome are needed.We prospectively studied 147 hepatocellular carcinoma patients (97
作者:Maria, Reig;Ferran, Torres;Carlos, Rodriguez-Lope;Alejandro, Forner;Neus, LLarch;Jordi, Rimola;Anna, Darnell;José, Ríos;Carmen, Ayuso;Jordi, Bruix
来源:Journal of hepatology 2014 年 61卷 2期